- Conditions
- Cutaneous Melanoma
- Interventions
- Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Surveillance, Ultrasound Imaging, Wide Local Excision
- Procedure · Other · Behavioral
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 75 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 181
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 142 more
Location Directory
Clinical trials in Cincinnati, Ohio
This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10564
Shown on this page
12
Current sort
Recently updated
Location scope
Cincinnati, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1081–1092 of 10,564 matching trials in Cincinnati, OH.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
- Conditions
- Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
- Interventions
- Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo
- Drug
- Lead sponsor
- Olema Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 62
- States / cities
- Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
- Conditions
- HIV -1 Infection
- Interventions
- GS-0415, GS-0415 Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami Lakes, Florida + 12 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
- Conditions
- Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
- Interventions
- DISC-0974, Placebo
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 29 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more
- Conditions
- Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
- Interventions
- Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 36
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia
- Interventions
- Catheter ablation
- Device
- Lead sponsor
- Heart Rhythm Clinical and Research Solutions, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 64 more